Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | F10 | P00742 | 3/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F5 | P12259 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503995 | 0.92 | L3MBTL1 (0.44) | L3MBTL1F10F2F5USP30 | |
| SCHEMBL4954432 | 0.90 | RAB9A (0.43) | L3MBTL1RAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL1504064 | 0.89 | GRM5 (0.38) | F10F2F5 | |
| SCHEMBL4260523 | 0.88 | L3MBTL1 (0.41) | L3MBTL1F10F2F5USP30 | |
| SCHEMBL4955372 | 0.87 | L3MBTL1 (0.44) | L3MBTL1F10F2F5USP30 | |
| SCHEMBL4955316 | 0.84 | KCNQ3 (0.36) | F10 | |
| SCHEMBL6891046 | 0.81 | PRMT5 (0.31) | MAPT | |
| SCHEMBL4952692 | 0.80 | L3MBTL1 (0.44) | L3MBTL1USP30RAB9ANPC1ALDH1A1 | |
| SCHEMBL715127 | 0.79 | L3MBTL1 (0.43) | L3MBTL1F10F2F5USP30 | |
| SCHEMBL368516 | 0.79 | L3MBTL1 (0.43) | L3MBTL1F10F2F5USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270446-A1 | DIAMINE DERIVATIVES | F2, TFPI, F3 | L3MBTL1 4055/4885F10 4/4885F2 1/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | L3MBTL1 385/4885F10 196/4885F2 4/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | L3MBTL1 385/4885F10 196/4885F2 4/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | L3MBTL1 385/4885F10 196/4885F2 4/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | L3MBTL1 309/4885F10 72/4885F2 4/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | L3MBTL1 4055/4885F10 4/4885F2 1/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | L3MBTL1 297/4885F10 138/4885F2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.